SCHEMBL1546573

SCHEMBL1546573

COc1cc2c(Oc3ccc(NS(=O)(=O)c4ccccc4Br)cc3F)ccnc2cc1OCCCN1CCN(C)CC1

nearest known ligand 0.88

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 19/20 0.88
EGFR P00533 7/20 0.82
MET P08581 7/20 0.82
SRC P12931 6/20 0.82
PLK4 O00444 2/20 0.80
AURKA O14965 2/20 0.80
GAK O14976 2/20 0.80
RIPK2 O43353 2/20 0.80
PRKAB2 O43741 2/20 0.80
ERN1 O75460 2/20 0.80
STK10 O94804 2/20 0.80
FYN P06241 2/20 0.80
YES1 P07947 2/20 0.80
LYN P07948 2/20 0.80
FER P16591 2/20 0.80
MARK3 P27448 2/20 0.80
MAP2K2 P36507 2/20 0.80
TGFBR2 P37173 2/20 0.80
CSK P41240 2/20 0.80
ABL2 P42684 2/20 0.80

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1546888 0.94 AXL (1.00) AXLEGFRMETSRCPLK4
SCHEMBL1546563 0.94 AXL (1.00) AXLEGFRMETSRCPLK4
SCHEMBL1592112 0.93 AXL (0.83) AXLEGFRMETSRC
SCHEMBL1591203 0.92 AXL (0.83) AXLEGFRMETSRCPLK4
SCHEMBL1546626 0.92 AXL (1.00) AXLEGFRMETSRCPLK4
SCHEMBL1546663 0.92 AXL (1.00) AXLEGFRMETSRCPLK4
SCHEMBL12705177 0.91 AXL (0.87) AXLEGFRMETSRCPLK4
SCHEMBL19060114 0.90 AXL (0.83) AXLEGFRMETSRCPLK4
SCHEMBL19060115 0.90 AXL (0.85) AXLEGFRMETSRCPLK4
SCHEMBL1547063 0.90 AXL (1.00) AXLEGFRMETSRCPLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2462117-B1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) 2017-06-28 EP claimed
US-9169241-B2 Quinolinyloxyphenylsulfonamides MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2015-10-27 US claimed
US-20140336191-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2014-11-13 US claimed
US-20120277231-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2012-11-01 US claimed
EP-2462117-A1 QUINOLINYLOXYPHENYLSULFONAMIDES Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2012-06-13 EP claimed
WO-2011045084-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2011-04-21 WO claimed
EP-2311809-A1 Quinolinyloxyphenylsulfonamides Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2011-04-20 EP claimed
EP-2462117-B1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) 2017-06-28 EP disclosed
EP-2462117-B1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) 2017-06-28 EP disclosed
US-9169241-B2 Quinolinyloxyphenylsulfonamides MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2015-10-27 US disclosed
US-9169241-B2 Quinolinyloxyphenylsulfonamides MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2015-10-27 US disclosed
US-9169241-B2 Quinolinyloxyphenylsulfonamides MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2015-10-27 US disclosed
US-20140336191-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2014-11-13 US disclosed
US-20120277231-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2012-11-01 US disclosed
US-20120277231-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2012-11-01 US disclosed
EP-2462117-A1 QUINOLINYLOXYPHENYLSULFONAMIDES Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2012-06-13 EP disclosed
WO-2011045084-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2011-04-21 WO disclosed
WO-2011045084-A1 QUINOLINYLOXYPHENYLSULFONAMIDES MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2011-04-21 WO disclosed
EP-2311809-A1 Quinolinyloxyphenylsulfonamides Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2011-04-20 EP disclosed
EP-2311809-A1 Quinolinyloxyphenylsulfonamides Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2011-04-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336191-A1 QUINOLINYLOXYPHENYLSULFONAMIDES TP53, AQP1, KRAS AXL 4326/4885EGFR 2891/4885MET 2187/4885
US-20120277231-A1 QUINOLINYLOXYPHENYLSULFONAMIDES TP53, AQP1, KRAS AXL 4326/4885EGFR 2891/4885MET 2187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.